Zolpidem hemitartarate - Biolab Sanus Farmaceutica
Alternative Names: Zolpidem hemitartarate orodispersibleLatest Information Update: 31 Oct 2021
Price :
$50 *
At a glance
- Originator Biolab Sanus Farmaceutica
- Class Acetamides; Hypnosedatives; Imidazoles; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sleep disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Sleep-disorders(In volunteers) in Brazil (PO, Tablet)
- 21 Mar 2019 Biolab Sanus Farmaceutica plans the phase II/III ZOLP_18_01 trial for Sleep maintenance insomnia, in September 2019 (NCT03885141)
- 28 Jun 2018 Chemical structure information added